- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04791618
MECA Clinical Intervention ( MECA Health360x) (MECAH360x)
Impact of Technology-based Intervention for Improving Self-management Behaviors in Black Adults; Sub-project of Biological and Socio-cultural Determinants and Management of Cardiovascular Health Factors in Multi-ethnic Populations
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study volunteers' participation in this study will last for 6 months. Investigators will ask participants to examine their own health behaviors. The purpose of the examination is to find the areas that need improvement so participants can work on them. Investigators will use technology in the form of Health360x to support participant efforts to change health behaviors.
This list below, shows the activities you will perform as part of this research.
Arm A ='High tech' Arm B='High tech high touch"
Recruitment Phone call: During this call, investigators will do the following:
- Collect email address
- Phone# that can receive text messages
- Contact information for 2 close friends/relatives
Investigators will email participants enrollment and welcome package that contains links to the
- Online screening form
- Consent form Please complete both forms
Investigators will send participants a link to online training videos and Health360x user manual that show how to use health360x and the online user manual
• Participants will show investigative team that they know how to use Health360x by completing a proficiency test
- Investigators will have Live chat sessions to answer questions about the project by the health coach and PI. Participants can access these as needed
- Participants will be assigned by chance, to High tech only(Arm A) or high tech and high touch(Arm B). Participant will receive an email notification of what study arm they are enrolled in
- Self- assessment; LS7 score
- Participant will receive a sleep/activity tracker; Investigators will work to obtain a Blood Pressure monitor through participants' usual health insurance
- Weekly goal setting; personal action plan x4 weeks Arm A participants will receive email prompts to complete. Arm B participants will complete; 45minute-1 hour meetings with health coach (recorded)
- Every 2-week goal setting; personal action plans x4 Arm A participants will receive email prompts to complete; Arm B participants will complete 45 minute-1 hour long meetings with health coach(recorded)
- Every 1 monthly goal setting; personal action plan x3 Arm A participants will receive email prompts to complete; Arm B participants will complete 45 minute-1 hour long meetings with health coach(recorded)
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30310
- Morehouse School of Medicine
-
Atlanta, Georgia, United States, 30322
- Emory University Clinical Research Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Already participating in baseline clinical study
- Volunteers with AHA LS7 scores of 4 or lower who have access to internet (community or personal),self-reported ability to participate in physical activity, and English fluency.
Exclusion Criteria:
- CAD documented by CAD diagnosis or prior acute myocardial infarction, percutaneous coronary intervention, coronary artery bypass surgery, or chronic angina; aortic stenosis; inability to participate in increased physical activity; history of alcohol or drug abuse or psychiatric diagnosis that would interfere with ability to participate.
Pregnant and/or breastfeeding women will be excluded. Cognitive deficits severe enough to preclude participation or any medical or surgical problem that precludes meaningful participation; unwillingness to use the internet
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Health360x only (High tech)
Access to Health360x technology only for 6 months Behavioral: Health360x Participants will receive Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self- management skills. Every participant will view an orientation video which will include information on how to access Health360 from home and other internet connected devices; how to use activity monitors provided by the study and sphygmomanometer. They will receive an introduction to heart health curriculum, quizzes and discussion forums. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the Helath360x application will be available online and by phone. The Health360x application will send messages to participants in this arm reminding them to perform study related activities. |
All participants will have access to Helath360x with reminders generated for goal setting.
Other Names:
|
|
Experimental: Health360x plus Coach (High tech High touch)
Health360x technology plus health coach Behavioral: Health360x plus health coach Participants will receive all of the resources in Arm A and Health coach interactions. The Health coach will send messages to participants in this arm reminding them to perform study related activities. The coach interactions will be focused on helping with attainment of self- management behaviors |
All participants will have access to Helath360x with reminders generated for goal setting.
Other Names:
Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self management skills
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Life Simple 7(LS7 the metrics for defining ideal cardiovascular health) score at 6-month follow-up
Time Frame: 6 months
|
The LS7 score consists of 4 behavioral and 3 clinical measures.
The behavioral measures are smoking, body Mass Index (BMI), physical activity and healthy dietary pattern.
The clinical measures are blood pressure, total cholesterol and fasting plasma glucose.Each LS7 component will be given a point score of 0, 1, or 2 to represent poor, intermediate, or ideal health, respectively.
Then, an overall LS7 score ranging from 0 to 14 will be calculated as the sum of the LS7 component scores.
The overall LS7 score will be further classified as inadequate (0-4), average (5-9), or optimum (10-14) cardiovascular health.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Diastolic Blood Pressure
Time Frame: Baseline, Month 6
|
Blood pressure readings will be made three times with the subject at rest in the sitting position using a cuff of the appropriate size and a standardized procedure.
The average of the three diastolic blood pressure measurements will be calculated.
Blood pressure will be categorized according to Joint National Committee recommendations.
|
Baseline, Month 6
|
|
Change in Delta Nutrition Intervention Research Initiative Food Frequency Questionnaire (Delta NIRI FFQ)
Time Frame: Baseline, Month 6
|
Dietary intake of fruits and vegetables will be assessed using the Lower Mississippi Delta Nutrition Intervention Research Initiative food frequency questionnaire (Delta NIRI FFQ).
The Delta NIRI FFQ is a 283-item, interviewer administered questionnaire that asks if respondents have had certain food items in the past 24 hours, including foods that are commonly consumed in the southern United States.
|
Baseline, Month 6
|
|
Change in Blood Glucose
Time Frame: Baseline, Month 3, Month 6
|
Blood glucose will be measured as milligrams per deciliter at Baseline, 3 months after the start of the intervention and at the end of the intervention at month 6.
Normal, fasting blood glucose levels are between 70 to 100 mg/dL.
|
Baseline, Month 3, Month 6
|
|
Change in Distance Walked Daily
Time Frame: Baseline, Month 3, Month 6
|
The total distance walked daily in miles will be measured by a pedometer or the exercise application for mobile devices.
|
Baseline, Month 3, Month 6
|
|
Change in Stress Management
Time Frame: Baseline, then monthly through Month 6
|
Participants will report on their stress management monthly via free text responses in an online format.
|
Baseline, then monthly through Month 6
|
|
Change in Weight
Time Frame: Baseline, then monthly through Month 6
|
Participants will report their weight in pounds once per month during the intervention period.
|
Baseline, then monthly through Month 6
|
|
Change in Tobacco Use
Time Frame: Baseline, then monthly through Month 6
|
Participants will report whether or not they have used tobacco once per month during the intervention period.
|
Baseline, then monthly through Month 6
|
|
Self management skills acquired
Time Frame: 6 months
|
Self management skills are patterned on the AADE 7 self care behaviors. A skill is acquired when the participant reports a score of 7 or higher on a 10-point scale. Healthy Coping Healthy Eating Being Active Monitoring Taking Medication Problem Solving Reducing Risks |
6 months
|
|
Change in Systolic Blood Pressure:
Time Frame: Baseline, Month 6
|
Blood pressure readings will be made three times with the subject at rest in the sitting position using a cuff of the appropriate size and a standardized procedure.
The average of the three systolic blood pressure measurements will be calculated.
Blood pressure will be categorized according to Joint National Committee recommendations.
|
Baseline, Month 6
|
|
Change in Short Form-12 Health Survey Questionnaire (SF-12) score
Time Frame: Baseline, Month 3, Month 6
|
The Short Form-12 Health Survey Questionnaire (SF-12) is a measure of general physical and mental health. The SF-12 consists of 12 items with a Likert-type response format that measures quality of life with a Physical Component Summary (PCS) and Mental Component Summary (MCS). Subscales associated with the PCS include physical functioning, role limitations due to physical problems, bodily pain, and general health perceptions. Subscales associated with the MCS include vitality (energy and fatigue), social functioning, role limitations due to emotional problems, and mental health. The total score for each subscale ranges from 0 to 100 and low values represent a poor health state while high values represent a good health state. |
Baseline, Month 3, Month 6
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Plasma Cysteine
Time Frame: Baseline, Month 6
|
Plasma cysteine is a biomarker of oxidative stress, which is implicated in the pathophysiology of multiple conditions including cardiovascular disease (CVD).
Higher levels of cysteine are associated with increased risk of CVD.
|
Baseline, Month 6
|
|
Change in Reactive Hyperemia Index (RHI)
Time Frame: Baseline, Month 6
|
Reactive Hyperemia Index (RHI) is a measure of microvascular endothelial function that is calculated as a ratio of preocclusion to postocclusion pulse signal amplitude.
RHI will be estimated using digital pulse amplitude tonometry (EndoPAT).
Greater RHI indicates better endothelial function.
|
Baseline, Month 6
|
|
Change in Glutathione
Time Frame: Baseline, Month 6
|
Glutathione is a major antioxidant that helps eliminate peroxides and maintain cellular redox.
Lower levels of glutathione are associated with cardiovascular disease.
|
Baseline, Month 6
|
|
Change in Augmentation Index
Time Frame: Baseline, Month 6
|
Augmentation index (AIx) is a composite measure of the magnitude of arterial wave reflections and systemic arterial stiffness and increases as the aortic pulse wave velocity (PWV) increases.
Impaired arterial elastic properties, measured as the aortic AIx and/or PWV, are increasingly recognized as independent predictors of incident CVD events (myocardial infarction, stroke, revascularization), as well as all-cause mortality.
|
Baseline, Month 6
|
|
Change in Carotid Intima Media Thickness (CIMT)
Time Frame: Baseline, Month 6
|
A CIMT scan is performed by using ultrasound determine the presence and severity of vascular disease.
Presence of carotid plaque is associated with a 2-3-fold increased risk of future CVD events, and increased CIMT is associated with prevalent cardiovascular disease and an increased risk of myocardial infarction and stroke.
Progression of CIMT has been used as a surrogate marker of change in CVD risk.
|
Baseline, Month 6
|
|
Change in High-sensitivity C-reactive Protein (HsCRP)
Time Frame: Baseline, Month 6
|
C-reactive protein (CRP) is a biomarker of cardiovascular health which increases in the blood when inflammation is present.
The Hs-CRP test can measure low levels of CRP which indicate the risk of developing cardiovascular disease (CVD).
A measurement of less than 1.0 milligrams of CRP per liter of blood (mg/L) is defined as low risk, 1.0 to 3.0 mg/ L is average risk, and above 3.0 mg/L is high risk of developing CVD
|
Baseline, Month 6
|
|
Change in Cystine
Time Frame: Baseline, Month 6
|
Cystine is the oxidized form of cysteine.
Higher plasma levels of cystine are associated with increased risk of CVD
|
Baseline, Month 6
|
|
. Change in CD34+ Cell Count
Time Frame: Baseline, Month 6
|
Cells expressing CD34 antigen (a protein encoded by the CD34 gene) are called CD34+ cells and can be isolated from blood samples.
CD34+ cell count is a biomarker of regenerative capacity and reduced counts of CD34+ is associated with increased cardiovascular risk.
|
Baseline, Month 6
|
|
Change in Pulse Wave Velocity (PWV)
Time Frame: Baseline, Month 6
|
Carotid-femoral artery pulse wave velocity (PWV) will be determined using transcutaneous Doppler flow velocity recordings simultaneously over the common carotid artery and the femoral artery.
Aortic pulse wave velocity (PWV) estimates of the speed of the pressure wave traveling along the aorta and is regarded as a direct measure of large artery stiffness.
Normal ranges for PWV are age based (PWV increases with age) and standardized thresholds for CVD risk have not been established.
This study will assess the change in PWV in participants between baseline and after the 6 month intervention
|
Baseline, Month 6
|
|
Change in circulating progenitor cells (CPC) CD34+/CD133+
Time Frame: Baseline, Month 6
|
Progenitor cells (PCs), including CD34+/CD133+ cells, are part of the mechanisms underlying regeneration, and the pivotal role they play in vascular repair has only recently been appreciated.
Endogenous PCs contribute to reendothelialization of tissues after endothelial injury, attenuating progression to frank atherosclerosis.
Endothelial dysfunction correlates with PC number and function and a low PC count appears to be an independent predictor of poor outcome in patients with CAD, stroke or acute lung injury.
CD34+/CD133+ cell counts improved risk prediction metrics beyond standard risk factors.
|
Baseline, Month 6
|
|
Change in circulating progenitor cells (CPCs) CD34+/VEGF2R+
Time Frame: Baseline, Month 6
|
Progenitor cells (PCs), including CD34+/VEGF2R+ cells, are part of the mechanisms underlying regeneration, and the pivotal role they play in vascular repair has only recently been appreciated.
Endogenous PCs contribute to reendothelialization of tissues after endothelial injury, attenuating progression to frank atherosclerosis.
Endothelial dysfunction correlates with PC number and function and a low PC count appears to be an independent predictor of poor outcome in patients with CAD, stroke or acute lung injury.
|
Baseline, Month 6
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Herman Taylor, MD, Morehouse School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 809392
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.